MXPA06000460A - Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b. - Google Patents

Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b.

Info

Publication number
MXPA06000460A
MXPA06000460A MXPA06000460A MXPA06000460A MXPA06000460A MX PA06000460 A MXPA06000460 A MX PA06000460A MX PA06000460 A MXPA06000460 A MX PA06000460A MX PA06000460 A MXPA06000460 A MX PA06000460A MX PA06000460 A MXPA06000460 A MX PA06000460A
Authority
MX
Mexico
Prior art keywords
beta
polypeptides
recombinant human
human interferon
ifn
Prior art date
Application number
MXPA06000460A
Other languages
English (en)
Inventor
Erno Pungor
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA06000460A publication Critical patent/MXPA06000460A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a polipeptidos humanos mejorados de interferon-beta-1b ("IFN-beta-1b"), O fragmentos, analogos, derivados o variantes de los mismos, que tienen actividad especifica mejorada. la presente invencion se refiere tambien a composiciones farmaceuticas que comprenden esos polipeptidos de IFN-beta-1b, o fragmentos, analogos, derivados o variantes de los mismos, utiles para tratar esclerosis multiple. La presente invencion se refiere a metodos para producir estas composiciones de IFN-beta-1b.
MXPA06000460A 2003-07-11 2004-07-06 Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b. MXPA06000460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48665703P 2003-07-11 2003-07-11
PCT/US2004/021618 WO2005016371A1 (en) 2003-07-11 2004-07-06 IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES

Publications (1)

Publication Number Publication Date
MXPA06000460A true MXPA06000460A (es) 2006-04-07

Family

ID=34193062

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000460A MXPA06000460A (es) 2003-07-11 2004-07-06 Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b.

Country Status (15)

Country Link
US (1) US20050008616A1 (es)
EP (1) EP1646397B1 (es)
JP (1) JP2007530419A (es)
KR (1) KR20060034286A (es)
CN (1) CN100408090C (es)
AU (1) AU2004264855A1 (es)
BR (1) BRPI0412477A (es)
CA (1) CA2528514A1 (es)
ES (1) ES2393783T3 (es)
IL (2) IL172269A0 (es)
MX (1) MXPA06000460A (es)
NO (1) NO20060675L (es)
RU (1) RU2006104023A (es)
WO (1) WO2005016371A1 (es)
ZA (1) ZA200601236B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573113A1 (en) * 2004-07-26 2006-02-09 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
EP1909822B1 (en) 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
WO2009045553A1 (en) * 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
CN103898123B (zh) * 2012-12-28 2019-03-15 北京韩美药品有限公司 重组人IFN-β-1a及其生产和纯化方法
CN108841793B (zh) * 2018-06-08 2021-08-27 东北农业大学 抗鸭Mx-A单克隆抗体及其在检测鸭Mx蛋白的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano

Also Published As

Publication number Publication date
US20050008616A1 (en) 2005-01-13
RU2006104023A (ru) 2006-07-27
AU2004264855A1 (en) 2005-02-24
EP1646397B1 (en) 2012-08-22
NO20060675L (no) 2006-04-06
CN100408090C (zh) 2008-08-06
CA2528514A1 (en) 2005-02-24
IL207422A0 (en) 2010-12-30
ES2393783T3 (es) 2012-12-28
IL172269A0 (en) 2006-04-10
WO2005016371A8 (en) 2006-06-15
EP1646397A1 (en) 2006-04-19
JP2007530419A (ja) 2007-11-01
CN1822852A (zh) 2006-08-23
WO2005016371A1 (en) 2005-02-24
BRPI0412477A (pt) 2006-09-19
KR20060034286A (ko) 2006-04-21
ZA200601236B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
HK1084404A1 (en) Muteins of tear lipocalin
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
AU8490901A (en) Urea compounds and methods of uses
DE60028970D1 (de) An her2 bindende peptidverbindungen
GB0222495D0 (en) Compounds
MXPA05007182A (es) Complejos de cristales de proteina y polimeros ionicos.
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
MXPA05010682A (es) Compuestos novedosos.
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
GEP20074197B (en) 5ht2c receptor modulators
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
TW200611695A (en) Pyrrolopyridine derivatives
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
EP1423414A4 (en) NEW DEPSIPEPTIDES AND METHOD FOR THE PRODUCTION THEREOF
SG149045A1 (en) Novel fused pyrrolocarbazoles
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
SG149042A1 (en) Novel fused pyrrolocarbazoles
HK1121670A1 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal